Carigent closes its $2mm Series A round
- Radiopharmaceuticals, Contrast Agents
- Controlled Release
- Site Specific
- Antisense, Oligonucleotides
- Nanotechnology, Chips, etc.
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.